The S1P1 receptor is the target of
four marketed drugs for the
treatment of multiple sclerosis and ulcerative colitis. Targeting
an S1P exporter, specifically Spns2, that is “upstream”
of S1P receptor engagement is an alternate strategy that might recapitulate
the efficacy of S1P receptor modulators without cardiac toxicity.
We recently reported the first Spns2 inhibitor SLF1081851 (16d) that has modest potency with in vivo activity. To develop more potent compounds, we initiated a structure–activity
relationship study that identified 2-aminobenzoxazole as a viable
scaffold. Our studies revealed SLB1122168 (33p), which is a potent inhibitor (IC50 = 94 ± 6 nM)
of Spns2-mediated S1P release. Administration of 33p to
mice and rats resulted in a dose-dependent decrease in circulating
lymphocytes, a pharmacodynamic indication of Spns2 inhibition. 33p provides a valuable tool compound to explore both the
therapeutic potential of targeting Spns2 and the physiologic consequences
of selective S1P export inhibition.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.